<DOC>
	<DOC>NCT01491529</DOC>
	<brief_summary>This study will assess the efficacy and safety of modified release AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Males and Females 3080 years old Use of highly effective methods of contraception during study in women of childbearing potential Outpatients Clinical diagnosis of Parkinson's Disease according to UK Parkinson's Disease Society Brain Bank Clinical Diagnosis criteria Score of &gt;/= 2 on UPDRS items 32 and 33 Dyskinesias for at least 3 months before baseline On stable treatment regimen with Ldopa and other antiparkinsonian treatment for 4 weeks prior to baseline Demonstrate capacity to complete accurate diary ratings Patients who have a primary caregiver willing to assess the condition of the patient throughout the study in accordance with protocol requirements Group 2 only: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study Atypical/secondary form of Parkinson's disease History of surgical treatment of PD, including deep brain stimulation A score of 5 in the "ON" state on the Modified Hoehn and Yahr scale Advanced, severe, or unstable disease other than PD Evidence of dementia Treatment with certain prohibited medications Amantadine within 2 weeks prior to BL1 visit (applies to Group 1 only) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Amantadine</keyword>
</DOC>